title: Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3.
abstract: Suppressor of cytokine signaling 3 (SOCS3) regulates the proinflammatory cytokine signaling mediated by the JAK/STAT signaling pathway. SOCS3 is rapidly induced and then targeted to the ubiquitin-proteasome pathway via a mechanism that requires the C-terminal SOCS box. Due to its rapid turnover, the intracellular stores of SOCS3 seem insufficient to control acute or protracted inflammatory diseases. Previously, we developed an intracellular protein therapy that uses a recombinant cell-penetrating form of SOCS3 (CP-SOCS3) to inhibit the JAK/STAT pathway and prevent cytokine-mediated lethal inflammation and apoptosis of the liver (Jo, D., Liu, D., Yao, S., Collins, R. D., and Hawiger, J. (2005) Nat. Med. 11, 892-898). The potent anti-inflammatory and cytoprotective activity of CP-SOCS3 prompted us to analyze its intracellular turnover, as compared with that of endogenous SOCS3 protein induced in macrophages by the proinflammatory agonists, interferon-gamma and lipopolysaccharide. We found that the half-life (t(1/2)) of endogenous SOCS3 is 0.7 h in activated macrophages, compared with a t(1/2) of 6.2 h for recombinant CP-SOCS3. Deletion of the SOCS box in CP-SOCS3 renders it more resistant to proteasomal degradation, extending its t(1/2) to 29 h. Consequently, this SOCS box-deleted form of CP-SOCS3 displays persistent inhibitory activity for 24 h toward interferon-gamma- and lipopolysaccharide-induced cytokine and chemokine production. Compared with the wild-type suppressor, this gain-of-function CP-SOCS3 mutant provides a longer acting inhibitor of cytokine signaling, a feature that offers a clear advantage for the intracellular delivery of proteins to treat acute or protracted inflammatory diseases.
authors.affiliation: Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee 37208, USA.
authors.forename: Tynetta C
authors.initials: TC
authors.lastname: Fletcher
authors.forename: Antonio
authors.initials: A
authors.lastname: DiGiandomenico
authors.forename: Jacek
authors.initials: J
authors.lastname: Hawiger
mesh_terms: D020816:Amino Acid Motifs; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry*; D017209:Apoptosis; D016207:Cytokines / Q000378:metabolism; D017353:Gene Deletion; D007249:Inflammation; D007371:Interferon-gamma / Q000378:metabolism; D008070:Lipopolysaccharides / Q000737:chemistry; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D021381:Protein Transport; D015398:Signal Transduction; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins / Q000378:metabolism*; D025801:Ubiquitin / Q000737:chemistry
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D008070:Lipopolysaccharides; C106644:SOCS3 protein, human; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins; D025801:Ubiquitin; D007371:Interferon-gamma
references.citation: J Biol Chem. 2004 Mar 19;279(12):11425-31
references.pmid: 14699109
references.citation: Mol Endocrinol. 2005 Apr;19(4):925-38
references.pmid: 15604114
references.citation: FEBS Lett. 2009 Aug 6;583(15):2486-92
references.pmid: 19589340
references.citation: Eur J Biochem. 1999 Oct 1;265(1):251-7
references.pmid: 10491180
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8043-7
references.pmid: 12060750
references.citation: Annu Rev Immunol. 2004;22:503-29
references.pmid: 15032587
references.citation: Mol Cell Biochem. 1995 Aug-Sep;149-150:17-27
references.pmid: 8569726
references.citation: Immunol Rev. 2008 Aug;224:265-83
references.pmid: 18759933
references.citation: Nat Med. 2005 Aug;11(8):892-8
references.pmid: 16007096
references.citation: J Biol Chem. 1995 Feb 3;270(5):2032-5
references.pmid: 7836429
references.citation: Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6493-8
references.pmid: 10829066
references.citation: Chest. 2000 Aug;118(2):503-8
references.pmid: 10936147
references.citation: J Biol Chem. 2009 Mar 27;284(13):8217-21
references.pmid: 19008218
references.citation: Nat Immunol. 2003 Jun;4(6):546-50
references.pmid: 12754506
references.citation: Curr Opin Chem Biol. 1999 Feb;3(1):89-94
references.pmid: 10021415
references.citation: J Biol Chem. 2003 Jan 24;278(4):2432-6
references.pmid: 12459551
references.citation: Mol Cell. 2006 Apr 21;22(2):205-16
references.pmid: 16630890
references.citation: Nat Immunol. 2003 Jun;4(6):540-5
references.pmid: 12754505
references.citation: Biochem Pharmacol. 2005 Sep 1;70(5):649-57
references.pmid: 15936728
references.citation: Immunol Res. 2001;23(2-3):99-109
references.pmid: 11444396
references.citation: Genes Cells. 1999 Jun;4(6):339-51
references.pmid: 10421843
references.citation: Genes Dev. 1998 Dec 15;12(24):3872-81
references.pmid: 9869640
references.citation: J Mol Biol. 2009 Mar 20;387(1):162-74
references.pmid: 19385048
references.citation: Nat Immunol. 2003 Dec;4(12):1169-76
references.pmid: 14639467
references.citation: EMBO J. 1999 Jan 15;18(2):375-85
references.pmid: 9889194
references.citation: Chest. 2000 Apr;117(4):1162-72
references.pmid: 10767254
references.citation: Sci Signal. 2009 Jul 21;2(80):ra37
references.pmid: 19622834
references.citation: Nat Rev Immunol. 2005 Jun;5(6):446-58
references.pmid: 15928677
references.citation: J Immunol. 2002 Aug 1;169(3):1219-27
references.pmid: 12133942
references.citation: Eur J Biochem. 2002 May;269(10):2516-26
references.pmid: 12027890
references.citation: Growth Factors. 2009 Dec;27(6):384-93
references.pmid: 19919527
references.citation: J Biol Chem. 2007 Nov 16;282(46):33494-33506
references.pmid: 17804406
references.citation: J Mol Biol. 2008 Sep 12;381(4):928-40
references.pmid: 18590740